产品
编 号：F364207
分子式：C16H21N7O
分子量：327.38
分子式：C16H21N7O
分子量：327.38
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
结构图
CAS No: 473930-22-2
产品详情
生物活性：
SM-276001 is a potent selective TLR7 agonist that can induce antitumor immune responses. SM-276001 is an orally active interferon (IFN) inducer.
体内研究：
SM-276001 demonstrates potent IFN-inducing activity at a dose of 0.1 mg/kg by oral administration in mice. Oral administration of SM-276001, leads to the induction of an inflammatory cytokine and chemokine milieu and to the activation of a diverse population of immune effector cells including T and B lymphocytes, NK and NKT cells. SM-276001 (3 mg/kgPO biweekly) significantly inhibits tumor growth in the Renca renal cell cancer and CT26 colorectal models. SM-276001 (orally; 0.1, 1 or 10 mg/kg) leads to the activation of a diverse population of spleen-resident immune effector cells in Balb/c and C57BL/6J mice. When administered at 1 mg/kg or greater, the plasma concentration of SM-276001 exceeds the MEC of 30 nM.Animal Model:C57BL/6 and B6C3F1 mice bearing Renca or CT26 tumors
Dosage:3 mg/kg
Administration:Oral administration twice weekly for 25 days
Result:Significantly reduced disease burden in mice bearing either Renca or CT26 tumors.
体外研究：
SM-276001 (1 nM-10 μM) dose-dependently activates NF-κB through human TLR7.
SM-276001 is a potent selective TLR7 agonist that can induce antitumor immune responses. SM-276001 is an orally active interferon (IFN) inducer.
体内研究：
SM-276001 demonstrates potent IFN-inducing activity at a dose of 0.1 mg/kg by oral administration in mice. Oral administration of SM-276001, leads to the induction of an inflammatory cytokine and chemokine milieu and to the activation of a diverse population of immune effector cells including T and B lymphocytes, NK and NKT cells. SM-276001 (3 mg/kgPO biweekly) significantly inhibits tumor growth in the Renca renal cell cancer and CT26 colorectal models. SM-276001 (orally; 0.1, 1 or 10 mg/kg) leads to the activation of a diverse population of spleen-resident immune effector cells in Balb/c and C57BL/6J mice. When administered at 1 mg/kg or greater, the plasma concentration of SM-276001 exceeds the MEC of 30 nM.Animal Model:C57BL/6 and B6C3F1 mice bearing Renca or CT26 tumors
Dosage:3 mg/kg
Administration:Oral administration twice weekly for 25 days
Result:Significantly reduced disease burden in mice bearing either Renca or CT26 tumors.
体外研究：
SM-276001 (1 nM-10 μM) dose-dependently activates NF-κB through human TLR7.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备